Scholarlink

Background <p>The biological distinction between first-episode psychosis (FEP) and chronic schizophrenia remains unclear. This study investigated a panel of non-canonical serum biomarkers related to neurodegeneration, neuroinflammation, and neurotrophic signaling across these clinical stages.</p> Methods <p>In a cross-sectional design, serum concentrations of 18 biomarkers were measured using multiplex immunoassay in 49 FEP patients, 80 patients with chronic schizophrenia (SCH), and 80 healthy controls (CON). Principal component analysis identified two major axes (neuroinflammatory-neurotrophic and synaptic), but the distributions of diagnostic groups overlapped substantially.</p> Results <p>A distinct biomarker profile was identified in FEP, characterized by significantly lower levels of YKL-40 and BDNF, elevated NCAM-1, decreased TDP-43, and a higher frequency of detectable Aβ1‑42 compared to both SCH and CON groups. In contrast, the SCH group did not differ from CON on most of these markers. Correlation analysis revealed a dense, interconnected biomarker network in SCH, centered on MIF and BDNF, while FEP exhibited a single strong correlation between TDP-43 and YKL-40. Principal component analysis identified two major axes (neuroinflammatory-neurotrophic and synaptic) but showed substantial overlap between diagnostic groups.</p> Conclusion <p>The findings reveal a unique, stage-dependent biological signature in early psychosis, differentiating FEP from both health and the chronic phase of illness. This supports the view of FEP as a distinct pathophysiological state involving dysregulated neuroinflammation, synaptic plasticity, and protein homeostasis, rather than merely a prodromal stage of chronic schizophrenia.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel perspective on biomarkers of neurodegeneration and neuroinflammation in first episode psychosis: a cross-sectional study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Valeria Zakurazhnaya,
  • Yana Zorkina,
  • Olga Abramova,
  • Daria Riabinina,
  • Alexandra Ochneva,
  • Valeriya Ushakova,
  • Alexander Reznik,
  • Georgy P. Kostyuk,
  • Anna Morozova

摘要

Background

The biological distinction between first-episode psychosis (FEP) and chronic schizophrenia remains unclear. This study investigated a panel of non-canonical serum biomarkers related to neurodegeneration, neuroinflammation, and neurotrophic signaling across these clinical stages.

Methods

In a cross-sectional design, serum concentrations of 18 biomarkers were measured using multiplex immunoassay in 49 FEP patients, 80 patients with chronic schizophrenia (SCH), and 80 healthy controls (CON). Principal component analysis identified two major axes (neuroinflammatory-neurotrophic and synaptic), but the distributions of diagnostic groups overlapped substantially.

Results

A distinct biomarker profile was identified in FEP, characterized by significantly lower levels of YKL-40 and BDNF, elevated NCAM-1, decreased TDP-43, and a higher frequency of detectable Aβ1‑42 compared to both SCH and CON groups. In contrast, the SCH group did not differ from CON on most of these markers. Correlation analysis revealed a dense, interconnected biomarker network in SCH, centered on MIF and BDNF, while FEP exhibited a single strong correlation between TDP-43 and YKL-40. Principal component analysis identified two major axes (neuroinflammatory-neurotrophic and synaptic) but showed substantial overlap between diagnostic groups.

Conclusion

The findings reveal a unique, stage-dependent biological signature in early psychosis, differentiating FEP from both health and the chronic phase of illness. This supports the view of FEP as a distinct pathophysiological state involving dysregulated neuroinflammation, synaptic plasticity, and protein homeostasis, rather than merely a prodromal stage of chronic schizophrenia.

Clinical trial number

Not applicable.